金吾财讯 | 再鼎医药(ZLAB)逆势上涨2.66%，最新报22.44美元，成交额309.77万美元。中金公司研究指，再鼎医药近期公布了3款在研肿瘤候选药物最新数据，包括zocilurtatugpelitecan(简称zoci，前称ZL-1310，DLL3ADC)、ZL-6201(LRRC15ADC)和ZL-1222(PD-1/IL-12双抗)，Zoci小肺颅内疗效和epNEC数据积极。机构维持2026年和2027年盈利预测不变，维持跑赢行业评级，且由于Zoci数据积极，机构上调Zoci未来销售峰值，基于DCF模型，上调H股/US股目标价15%/15%至22.0港元/28.4美元，较当前股价有16.8%/24.2%上行空间。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.